Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts

Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts

Item
http://www.wikidata.org/entity/Q35270758
Epidemiology of candidemia in Latin America: a laboratory-based survey.Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimensDose escalation studies with caspofungin against Candida glabrata.Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis.Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model.In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infectionUse of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole.The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination.Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactionsPharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with EchinocandinsSignificantly Improved Pharmacokinetics Enhances Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive CandidiasisFungal Resistance to Echinocandins and the MDR Phenomenon in
P2860

Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts

Item
http://www.wikidata.org/entity/Q35270758
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacodynamics of echinocand ...... activity in neutropenic hosts
@ast
Pharmacodynamics of echinocand ...... activity in neutropenic hosts
@en
type
label
Pharmacodynamics of echinocand ...... activity in neutropenic hosts
@ast
Pharmacodynamics of echinocand ...... activity in neutropenic hosts
@en
prefLabel
Pharmacodynamics of echinocand ...... activity in neutropenic hosts
@ast
Pharmacodynamics of echinocand ...... activity in neutropenic hosts
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Pharmacodynamics of echinocand ...... activity in neutropenic hosts
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932